Last Updated : May 23, 2019
CADTH has received some inquiries regarding how and when patient groups are re-engaged in the CADTH Common Drug Review (CDR) process following an initial call for patient input. In the case of a pending submission or resubmission, CADTH will repost the call for patient input in the following circumstances:
In most instances, patient groups may want to simply resubmit their earlier input. CADTH appreciates that this may require some additional effort for patient groups, but feels that re-posting the call for patient input in the above-noted circumstances is important for the following reasons: it ensures that the patient group input reflects the current perspective from the patient group(s) who initially responded; and it provides an opportunity for any additional groups to contribute to the CADTH review process.
In the case of a request for advice, CADTH posts a call for patient input and reaches out directly to all patient groups who provided input on the original CADTH review of the drug.
When CADTH launched a new, streamlined biosimilar review process in February 2018, we committed to evaluating the impact and utility of the new process after approximately one year. CADTH recently completed this internal evaluation, which included consultation with public drug plans and the pan-Canadian Pharmaceutical Alliance (pCPA). As a result, CADTH is pleased to announce that there is no longer a need for CADTH to continue offering the streamlined biosimilar review process. There are no changes to the current pCPA negotiation process anticipated as a result of the decision by CADTH.
As of June 1, 2019, CADTH will be stopping work on any biosimilar reviews that would have been completed after June 1, 2019.
This decision was made based for several compelling reasons, including the fact that the current streamlined biosimilar review process may delay access to new biosimilar treatments. Stopping the biosimilar review process will allow CADTH to redeploy its limited resources that are being used to administer the biosimilar process to other drug reviews and program-related issues.
Effective immediately, submissions for biosimilars should be filed directly with the jurisdictions and pCPA. There may be rare circumstances where a CADTH review may be required for a biosimilar (e.g., the reference product was not reviewed by CADTH or a drug plan); CADTH and the drug plans would consider these on a case-by-case basis. Any manufacturers with questions regarding eligibility for biosimilar submissions should contact CADTH (email@example.com).
On February 28, 2019, CADTH — in collaboration with the Canadian Association of Provincial Cancer Agencies — issued a consultation proposal to integrate key functions of the Cancer Drug Implementation Advisory Committee into the CADTH pCODR process. We would like to thank all stakeholders who responded to the consultation. CADTH continues to assess all stakeholder feedback and is taking a balanced approach to ensure that the application of these comments would be made in the best interest of patients and the public.
We are working to target an implementation date of July 1, 2019, whereby any pre-submission information form received by the pCODR program on or after July 1, 2019 will incorporate the proposed implementation functions. CADTH will issue a notice prior to the implementation of any applicable changes to CADTH pCODR procedures and guidelines, so as to reduce the impact of timing on those working on submissions to the process. Revised processes and guideline documents should be publicly available on the CADTH website on June 12, 2019.
CADTH has encountered several challenges with the existing redaction request process for the clinical and pharmacoeconomic review reports, including the following:
As noted in the CADTH August 2018 consultation on posting manufacturer comments, the agency is interested in ensuring that the redaction process avoids the need for multiple redaction requests. As such, CADTH has revised the CDR procedure to shift the timing of the redaction request process to after the CADTH Drug Expert Committee (CDEC) Final Recommendation has been issued. This will allow manufacturers the opportunity to review and request redactions from the final CADTH review reports, eliminating the issues noted previously, and making the process more efficient for both CADTH and manufacturers.
This new process is effective for all submissions, resubmissions, and requests for advice that were filed on or after May 1, 2019.
Details regarding the new redaction process for CDR documents have been incorporated into an updated version of the Procedure and Submission Guidelines for the CADTH Common Drug Review.
CADTH has recently encountered an increasing number of situations where applicants are not providing details of the economic evaluation when filing advance notification forms. This information is required in order for CADTH to prepare resources for the pending submission or resubmission. CADTH appreciates that this information may be incomplete when the advance notification form is initially filed; however, manufacturers are not following up with the complete details prior to filing the submission or resubmission.
Effective immediately, if the economic information is incomplete when initially submitting the advanced notification form, this information should be updated as soon as possible and submitted to CADTH no later than two weeks prior to filing the submission or resubmission.
CADTH has updated the template used for the clinical reports prepared for standard reviews. Revisions include a new stakeholder input section that will summarize information from patient groups and clinicians earlier in the report, and moving evidence from non-randomized studies and indirect comparisons from the appendices into the main body of the report. Please see the link that follows for a sample of the new CADTH template:
CADTH is pleased to announce that a representative from Canadian Blood Services (CBS) has been added as an observer to the DPAC Formulary Working Group. The addition of CBS to this working group will allow CADTH, CBS, and the public drug plans to further collaborate, sharing information on drug topics that are of interest to all parties. The DPAC Formulary Working Group list has been updated to reflect this change.
The Procedure and Submission Guidelines for the CADTH Common Drug Review has been updated with the following revisions:
Applicants who have questions about specific requirements may contact CADTH for guidance on submission preparation by emailing firstname.lastname@example.org.